Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Artemisinin Antimalarial Drugs Market

Artemisinin Antimalarial Drugs Market Share

Report ID: GMI10811
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Artemisinin Antimalarial Drugs Market Share

The competitive landscape of the artemisinin antimalarial drugs industry is characterized by a diverse mix of pharmaceutical companies and research institutions striving to innovate and expand their market presence. Key players in this sector include pharmaceutical giants like Novartis and Sanofi, which have established themselves as leading suppliers of artemisinin-based combination therapies (ACTs). These companies leverage their extensive distribution networks and substantial R&D investments to maintain a competitive edge.

Additionally, smaller biotech firms and emerging players are actively involved in developing new formulations and improving the efficacy of existing treatments. Strategic collaborations, partnerships, and ongoing research into novel drug combinations and delivery methods are pivotal in shaping the competitive dynamics and driving advancements in the market.

Artemisinin Antimalarial Drugs Market Companies

Few of the prominent players operating in industry include:

AdvaCare Pharma USA LLC
Calyx Chemicals and Pharmaceuticals Ltd.
Cipla Limited
Guilin Pharmaceutical Co., Ltd.
Ipca Laboratories Ltd.
KPC Pharmaceuticals, Inc.
Novartis AG
Rusan Pharma Ltd.
Sanofi S.A.
Shin Poong Pharmaceutical Co., Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for artemisinin antimalarial drugs was valued at USD 672.2 million in 2023 and is anticipated to register 4.2% CAGR between 2024 and 2032 due to the rising incidence of malaria particularly in tropical and subtropical regions.

The combination therapy segment in the artemisinin antimalarial drugs market is projected to reach USD 660.7 million by 2032 due to its enhanced efficacy in treating malaria, addressing drug resistance, and leveraging synergistic effects of multiple antimalarial agents.

Middle East & Africa market is projected to record 4.1% CAGR through 2032 due to the high prevalence of malaria in several countries and increasing investments in healthcare infrastructure.

AdvaCare Pharma USA LLC, Calyx Chemicals and Pharmaceuticals Ltd., Cipla Limited, Guilin Pharmaceutical Co., Ltd., Ipca Laboratories Ltd., KPC Pharmaceuticals, Inc., Novartis AG, and Rusan Pharma Ltd., among others.